Routine HIV Screening - What Counts in Evidence-Based Policy?
NEJM 365:1265-1268, Bayer, R. and Oppenheimer G.M., 2011
AIDS - Related Lymphomas: Primary CNS Lymphoma
UpToDate, April, Doweiko, J.P., 2010
Corticosteroids for Acute Bacterial Meningitis
NEJM 357:2507-2509, Greenwood,B.M., 2007
Therapeutic Dilemma
Neurol 54:1404-1407, Romanelli,F.,et al, 2000
Intracranial Mass Lesions in AIDS:Using Decision Analysis to Determine the Effectiveness of Stereotactic Brain Biopsy
Neurol 46:1010-1015, Holloway,R.G.,et al, 1996
Double-Blind Study with Levorotatory form of Hydroxytryptophan in Pts with Degen Cerebellar Dis
Arch Neurol 52:451-455, 4401995., Wessel,K.,et al, 1995
Severe Acute Respiratory Syndrome Coronavirus 2 Infection and Ischemic Stroke
Stroke 51:e124-e127, Valdes Valderrama, E.,et al, 2020
Infective Endocarditis
Lancet 387:882-893, Cahill, T.J. & Prendergast, B.D., 2016
Update on the Pathophysiology and Management of Idiopathic Intracranial Hypertension
JNNP 83:488-494, Biousse,V.,et al, 2012
Optic Neuritis: Prognosis and Treatment
UpToDate, Jan, Osborne, B.,et al, 2011
Immune Reconstitution Inflammatory Syndrome in Natalizumab-Associated PML
Neurol 77:1061-1067,1033, Tan, I.L.,et al, 2011
Open Biopsy in Patients With Acute Progressive Neurologic Decline and Absence of Mass Lesion
Neurol 75:419-424, Schuette,A.J., et al, 2010
Natalizumab: A Double-Edged Sword?
Ann Neurol 66:262-263, DeAngelis,L., 2009
Best Practice Recommendations for the Selection and Management of Patients with Multiple Sclerosis Receiving Natalizumab Therapy
Mutliple Sclerosis 15:S26-S36, Coyle,P.K.,et al, 2009
Invited Article: Changing Concepts in Parkinson Disease: Moving Beyond the Decade of the Brain
Neurol 70:1996-2003, Marras,C. &Lang,A., 2008
Optic Pathway Gliomas in Neurofibromatosis-1: Controversies and Recommendations
Ann Neurol 61:189-198, Listernick,R.,et al, 2007
What Went Wrong in the Natalizumab Trials?
Lancet 367:706-709, Langer-Gould,A.&Steinman,L., 2006
Simultaneous Carotid Endarterectomy and Coronary Artery Bypass Surgery in Canada
Neurol 64:1435-1437,1332, Hill,M.D.,et al, 2005
Interferons in Relapsing Remitting Multiple Sclerosis: A Systematic Review
Lancet 361:545-552, Filippini,G.,et al, 2003
Smallpox, Bioterrorism, and the Neurologist
Arch Neurol 60:489-494, Cleri,D.J.,et al, 2003
Effect of Early Interferon Treatment on Conversion to Definite Multiple Sclerosis: A Randomised Study
Lancet 357:1576-1582,1547, Comi,G.,et al, 2001
Measurement of Antibodies to Interferon Beta in Patients With Multiple Sclerosis
Arch Neurol 58:1299-1300,1301, Pachner,A.R., 2001
The Significance of Neutralizing Antibodies in Patients With Multiple Sclerosis Treated With Interferon Beta
Arch Neurol 58:1297-1298,1301, Rice,G., 2001
Trauma Does Not Precipitate Multiple Sclerosis
Arch Neurol 57:1077-1078, Cook.S.D., 2000
Trauma to the Central Nervous System May Result in Formation or Enlargement of Multiple Sclerosis Plaques
Arch Neurol 57:1074-1076,1078, Poser,C.M., 2000
Intravenous Immunoglobulin Treatment in Neurologic Disorders
Arch Neurol 56:1025-1027,1032, Sorensen,P.S., 1999
Population Based Cost Utility Study of Interferon Beta-1b in Secondary Progressive Multiple Sclerosis
BMJ 319:1529-1533, Forbes,R.B.,et al, 1999
Interferons in the Treatment of Multiple Sclerosis,Do They Prevent the Progression of the Disease?
Arch Neurol 55:1578-1580,1583, Rice,G.&Ebers,G, 1998
Interferons Should be Used to Treat Most Patients with MS
Arch Neurol 55:1581-1583, Herndon,R.M.&Jacobs,L, 1998
Frontotemporal Degeneration, Pick Disease, and Corticobasal Degeneration
Arch Neurol 54:1425-1427, 14291997., Neary,D., 1997
Frontotemporal Dementia, Pick Disease, and Corticobasal Degeneration
Arch Neurol 54:1427-1429, Kertesz,A., 1997
Environmental Causation of Parkinson's Disease
Arch Neurol 50:651-652, Rajput,A.H., 1993
Yes, Brain Biopsy Should be a Prerequisite for Herpes Simplex Encephalitis Treatment
Arch Neurol 44:1289-1292, Hanley,D.F.,et al, 1987